1Yokoshiki H,Katsube Y,Sunagawa M,et al.Levosimendan,a novel Ca2+ sensitizer,activates the glibenclamide-sensitive K+channel in rat arterial myocytes[J].Eur J Pharmacol,1997,333:249-259.
2Nieminen MS,Akkila J,Hasenfuss G,et al.Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure[J].J Am Coll Cardiol,2000,36:1903-1912.
3Slawsky MT,Colucci WS,Gottlieb SS,et al.For the Study Investigators.Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure[J].Circulation,2000,102:2222-2227.
4Packer M,Colucci WS,Fisher L,et al.Development of a comprehensive new end point for the evaluation of new treatments for acute decompensated heart failure:results with levosimendan in the REVIVE-1 study[J].J Card Fail,2003,9:S61.
5Packer M.Multicenter Placebo-Controlled Trial of Levosimendan on Clinical Status in Acutely Decompensated Heart Failure:REVIVE II[R].American Heart Association Scientific Sessions,Dallas,USA,November,2005.
6Mebazaa A.The Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support:SURVIVE[R].American Heart Association Scientific Sessions,Dallas,USA,November,2005.
7Coletta AP,Cleland JG,Freemantle N,et al.Clinical trials update from the European Society of Cardiology Heart Failure meeting:SHAPE,BRING-UP 2 VAS,COLA II,FOSIDIAL,BETACAR,CASINO and meta-analysis of cardiac resynchronisation therapy[J].Eur J Heart Fail,2004,6:673-676.
8Follath F,Cleland JG,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study):a randomised double-blind trial[J].Lancet,2002,360:196-202.
9Nanas JN,Papazoglou PP,Terrovitis JV,et al.Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone[J].Am J Cardiol,2004,94:1329-1332.
10Franco F,Gon?alves F,Castro G,et al.Levosimendan is efficacious in acute heart failure independent of renal function[J].Eur Heart J,2003,24(suppl):408.
2Haikala H,Kaivola J,Nissinen E,et al.Cardiactroponin C as a target protein for a novel calcium sensitizing drug,levosimendan[J].J Mol Cell Cardiol,1995,27(9):1859-1866.
3Ferenc F.Newer treatments for decompensated heart failure:Focus on levosimendan[J].Drug Des Devel Ther,2009,3:73-78.
4Follath F,Cleland JG,Just H,et al.Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure(the LIDO study):A randomized double-blind trial[J].Lancet,2002,360(9328):196-202.
5Claes-Hkan Bergh,Bert Andersson,Ulf Dahlstrm,et al.Intravenous levosimendan vs.dobutamine in acute decompensated heart failure patients on beta-blockers[J].Eur J Heart Fail,2010,12(4):404-410.
6Duman D,Palit F.Comparative effects of levosimendan and dobutamine on left ventricular diastolic function and brain natriuretic peptide in patients with decompensated advanced heart failure[J].Eur Heart J,2009,30:P348.
7Moiseyev VS,Poder P,Andrejevs N,et al.Safety and efficacy of a novel calcium sensitizer,levosimendan,in patients with left ventricular failure due to an acute myocardial infarction:A randomized,placebo-controlled,doubleblind study(RUSSLAN)[J].Eur Heart J,2002,23(18):1422-1432.
8Cohen-Solal A,Logeart D,Huang B,et al.Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure[J].J Am Coll Cardiol,2009,53(25):2343-2348.
10Fries M,Ince C,Rossaint R,et al.Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock[J].Crit Care Med,2008,36(6):1886-1891.
